$1.39
+0.04
(+2.96%)▲
2.98%
Downside
Day's Volatility :3.67%
Upside
0.71%
57.54%
Downside
52 Weeks Volatility :94.19%
Upside
86.31%
Period | Aclaris Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 12.5% | 6.5% | 0.0% |
6 Months | 9.76% | 7.1% | 0.0% |
1 Year | -86.32% | 9.8% | 0.0% |
3 Years | -91.07% | 14.2% | -20.2% |
Market Capitalization | 98.7M |
Book Value | $1.99 |
Earnings Per Share (EPS) | -1.09 |
PEG Ratio | -0.13 |
Wall Street Target Price | 1.84 |
Profit Margin | -248.28% |
Operating Margin TTM | -672.69% |
Return On Assets TTM | -31.9% |
Return On Equity TTM | -48.47% |
Revenue TTM | 31.1M |
Revenue Per Share TTM | 0.44 |
Quarterly Revenue Growth YOY | -5.1% |
Gross Profit TTM | -60.0M |
EBITDA | -117.6M |
Diluted Eps TTM | -1.09 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.8 |
EPS Estimate Next Year | -0.62 |
EPS Estimate Current Quarter | -0.29 |
EPS Estimate Next Quarter | -0.25 |
What analysts predicted
Upside of 32.37%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 10.1M | ↑ 499.58% |
Net Income | -132.7M | ↑ 93.71% |
Net Profit Margin | -1.3K% | ↑ 2756.07% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 4.2M | ↓ 58.11% |
Net Income | -142.9M | ↑ 7.62% |
Net Profit Margin | -3.4K% | ↓ 2064.06% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 6.5M | ↑ 53.35% |
Net Income | -51.2M | ↓ 64.19% |
Net Profit Margin | -789.17% | ↑ 2590.3% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 6.8M | ↑ 4.3% |
Net Income | -114.3M | ↑ 123.41% |
Net Profit Margin | -1.7K% | ↓ 901.13% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 29.8M | ↑ 340.05% |
Net Income | -88.7M | ↓ 22.42% |
Net Profit Margin | -298.0% | ↑ 1392.3% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 31.2M | ↑ 5.03% |
Net Income | -88.5M | ↓ 0.2% |
Net Profit Margin | -283.15% | ↑ 14.85% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 7.8M | ↓ 59.23% |
Net Income | -33.3M | ↑ 56.81% |
Net Profit Margin | -429.4% | ↓ 317.77% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.5M | ↓ 67.39% |
Net Income | -26.4M | ↓ 20.69% |
Net Profit Margin | -1.0K% | ↓ 614.98% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.9M | ↓ 26.07% |
Net Income | -29.6M | ↑ 12.0% |
Net Profit Margin | -1.6K% | ↓ 537.7% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.3M | ↑ 396.63% |
Net Income | -29.3M | ↓ 1.04% |
Net Profit Margin | -315.24% | ↑ 1266.84% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 17.6M | ↑ 89.29% |
Net Income | -1.5M | ↓ 94.9% |
Net Profit Margin | -8.49% | ↑ 306.75% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 2.4M | ↓ 86.35% |
Net Income | -16.9M | ↑ 1036.22% |
Net Profit Margin | -706.46% | ↓ 697.97% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 275.6M | ↑ 13.16% |
Total Liabilities | 60.4M | ↑ 231.24% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 98.3M | ↓ 64.33% |
Total Liabilities | 28.4M | ↓ 53.04% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 70.8M | ↓ 27.99% |
Total Liabilities | 33.1M | ↑ 16.73% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 251.2M | ↑ 254.9% |
Total Liabilities | 53.9M | ↑ 62.58% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 254.6M | ↑ 1.35% |
Total Liabilities | 57.0M | ↑ 5.76% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 197.4M | ↓ 22.46% |
Total Liabilities | 40.2M | ↓ 29.4% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 254.6M | ↓ 4.87% |
Total Liabilities | 57.0M | ↑ 19.21% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 229.7M | ↓ 9.78% |
Total Liabilities | 52.9M | ↓ 7.16% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 235.6M | ↑ 2.59% |
Total Liabilities | 55.9M | ↑ 5.68% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 218.4M | ↓ 7.34% |
Total Liabilities | 62.0M | ↑ 10.95% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 197.4M | ↓ 9.59% |
Total Liabilities | 40.2M | ↓ 35.14% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 174.1M | ↓ 11.82% |
Total Liabilities | 32.1M | ↓ 20.32% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -100.8M | ↑ 84.42% |
Investing Cash Flow | 9.4M | ↓ 116.82% |
Financing Cash Flow | 128.3M | ↑ 27.77% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -96.4M | ↓ 4.33% |
Investing Cash Flow | 105.7M | ↑ 1028.21% |
Financing Cash Flow | -30.3M | ↓ 123.64% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -38.6M | ↓ 59.94% |
Investing Cash Flow | 6.4M | ↓ 93.96% |
Financing Cash Flow | 18.4M | ↓ 160.6% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -52.1M | ↑ 34.95% |
Investing Cash Flow | -167.6M | ↓ 2724.58% |
Financing Cash Flow | 225.1M | ↑ 1124.97% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -67.6M | ↑ 29.6% |
Investing Cash Flow | 12.6M | ↓ 107.53% |
Financing Cash Flow | 72.9M | ↓ 67.62% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -19.1M | ↑ 144.53% |
Investing Cash Flow | 2.7M | ↑ 122.02% |
Financing Cash Flow | 37.0K | ↓ 436.36% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -26.4M | ↑ 37.87% |
Investing Cash Flow | 25.8M | ↑ 854.77% |
Financing Cash Flow | 26.7M | ↑ 72181.08% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -20.7M | ↓ 21.63% |
Investing Cash Flow | -19.7M | ↓ 176.22% |
Financing Cash Flow | 26.7M | ↑ 0.0% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -24.6M | ↑ 18.9% |
Investing Cash Flow | 32.5M | ↓ 265.47% |
Financing Cash Flow | -87.0K | ↓ 100.33% |
Sell
Neutral
Buy
Aclaris Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Aclaris Therapeutics Inc | 21.08% | 9.76% | -86.32% | -91.07% | -22.86% |
![]() Idexx Laboratories, Inc. | -3.67% | -10.34% | -15.37% | -31.35% | 65.77% |
![]() Agilent Technologies Inc. | 1.42% | 3.05% | 5.07% | -10.16% | 94.22% |
![]() Thermo Fisher Scientific, Inc. | 6.51% | 8.62% | 3.5% | 12.36% | 106.99% |
![]() Danaher Corp. | 6.51% | 15.92% | 1.97% | -6.92% | 89.83% |
![]() Iqvia Holdings Inc. | 10.0% | 7.5% | 0.14% | -6.07% | 45.29% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Aclaris Therapeutics Inc | NA | NA | -0.13 | -0.8 | -0.48 | -0.32 | NA | 1.99 |
![]() Idexx Laboratories, Inc. | 45.67 | 45.67 | 4.75 | 11.06 | 0.72 | 0.23 | NA | 18.93 |
![]() Agilent Technologies Inc. | 31.63 | 31.63 | 2.7 | 5.2 | 0.21 | 0.08 | 0.01 | 21.31 |
![]() Thermo Fisher Scientific, Inc. | 35.72 | 35.72 | 2.81 | 21.71 | 0.14 | 0.05 | 0.0 | 120.87 |
![]() Danaher Corp. | 48.76 | 48.76 | 3.13 | 6.99 | 0.08 | 0.04 | 0.0 | 68.92 |
![]() Iqvia Holdings Inc. | 30.13 | 30.13 | 1.33 | 11.19 | 0.23 | 0.05 | NA | 36.83 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Aclaris Therapeutics Inc | Hold | $98.7M | -22.86% | NA | -248.28% |
![]() Idexx Laboratories, Inc. | Buy | $38.8B | 65.77% | 45.67 | 23.26% |
![]() Agilent Technologies Inc. | Buy | $38.9B | 94.22% | 31.63 | 18.84% |
![]() Thermo Fisher Scientific, Inc. | Buy | $219.4B | 106.99% | 35.72 | 14.2% |
![]() Danaher Corp. | Buy | $191.9B | 89.83% | 48.76 | 17.83% |
![]() Iqvia Holdings Inc. | Buy | $42.3B | 45.29% | 30.13 | 9.39% |
Insights on Aclaris Therapeutics Inc
Revenue is down for the last 2 quarters, 17.57M → 2.39M (in $), with an average decrease of 86.4% per quarter
Netprofit is down for the last 2 quarters, -1.49M → -16.94M (in $), with an average decrease of 1036.2% per quarter
In the last 1 year, Agilent Technologies Inc. has given 5.1% return, outperforming this stock by 91.4%
In the last 3 years, Aclaris Therapeutics Inc has experienced a drawdown of -91.1%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 80.9%
BML Capital Management LLC
BlackRock Inc
Vanguard Group Inc
D. E. Shaw & Co LP
Millennium Management LLC
Bain Capital Life Sciences Investors, LLC
aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.
Organization | Aclaris Therapeutics Inc |
Employees | 86 |
CEO | Dr. Neal S. Walker D.O., M.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$1.39
+2.96%
Keyarch Acquisition Corp
$1.39
+2.96%
Connexa Sports Technologies Inc
$1.39
+2.96%
Us Value Etf
$1.39
+2.96%
First Wave Biopharma Inc
$1.39
+2.96%
Global X Msci Next Emerging
$1.39
+2.96%
Fat Projects Acquisition Corp
$1.39
+2.96%
Capital Link Global Fintech
$1.39
+2.96%
Applied Uv Inc
$1.39
+2.96%